Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Repligen Corporation Q4 2025 Earnings Call - Returned to robust growth, guiding cautiously into 2026 with margin expansion and M&A optionality
Repligen closed 2025 with a strong finish, reporting Q4 revenue of $198 million (14% organic growth) and full-year revenue of $738 million. Management said the company outperformed October guidance, d...
- Q4 revenue $198 million, up 18% reported and 14% organic; full-year revenue $738 million, up 16% reported and organic non-COVID, 14% organic.
- Repligen beat the high end of its October guidance for both revenue and adjusted operating income, citing broad portfolio momentum and stronger order trends into Q4.
- Proteins and analytics were the engines of growth, proteins up >30% in Q4 and 31% for the year, analytics >30% in Q4 and 37% for the year (21% excluding M&A).
- +14 more takeaways
Establishment Labs Q4 2025 Earnings Call - US Motiva Momentum Drives Profitability and 2026 Guidance $264–266M
Establishment Labs closed 2025 with a fast-growing U.S. rollout that pushed revenue to $211.1 million, up 27.2% year over year, and carved out a path to sustained profitability. Q4 revenue was $64.6 m...
- Q4 2025 revenue was $64.6 million, up 45.2% versus Q4 2024, driving full-year 2025 revenue of $211.1 million, up 27.2% year over year.
- U.S. Motiva revenue for 2025 totaled $45.6 million, with Q4 U.S. Motiva sales of $17.3 million, a faster adoption curve than investors expected.
- Gross profit in Q4 was $45.5 million, or 70.5% of revenue, marking a 200 basis point improvement year over year and a 330 basis point improvement for all of 2025 versus 2024.
- +13 more takeaways
Ziff Davis Q4 and FY2025 Earnings Call - Search-driven Affiliate Hit Keeps Tech & Shopping in the Doghouse
Ziff Davis posted modest full-year growth while a search-driven collapse in affiliate commerce carved into Q4 results. FY2025 revenue rose 3.5% to $1.45 billion and adjusted EBITDA edged up to $495.1 ...
- Full year 2025 revenue rose 3.5% to $1,451.3 million, and adjusted EBITDA increased to $495.1 million, with an FY adjusted EBITDA margin of 34.1%.
- Q4 2025 revenue was $406.7 million, down 1.5% year-over-year, and Q4 adjusted EBITDA fell 5% to $163.2 million, with a Q4 adjusted EBITDA margin of 40.1%.
- Tech and Shopping was the clear drag, down 18% in Q4, driven primarily by a decline in web search traffic that materially reduced affiliate commerce commissions.
- +14 more takeaways
Arvinas Q4 2025 Earnings Call - Company pivots to four Phase I programs, eyes multiple 2026 data readouts
Arvinas used its Q4 2025 results call to signal a clear strategic reset: the company is now a predominantly Phase I clinical-stage biotech, concentrating resources on four clinical programs while keep...
- Arvinas is repositioned as a Phase I-focused company, concentrating on four clinical programs: ARV-102 (LRRK2), ARV-806 (KRAS G12D), ARV-393 (BCL6) and ARV-027 (polyQ AR for SBMA).
- Management expects multiple meaningful data readouts and clinical advancements across 2026 that will determine program prioritization and value creation.
- ARV-102 (LRRK2 degrader) achieved brain penetration and showed greater than 50% LRRK2 reduction in CSF in earlier studies; patient biomarker data will be presented at the AD/PD conference and a Phase 1b in PSP is planned for H1 2026.
- +11 more takeaways
Scotiabank Q1 2026 Earnings Call - ROE Ahead of Plan as Credit Costs Stay Elevated
Scotiabank posted a strong start to fiscal 2026, delivering adjusted earnings of CAD 2.7 billion and EPS of CAD 2.05, with return on equity at 13% and CET1 at 13.3% after buybacks. Management says the...
- Adjusted net income CAD 2.7 billion, diluted EPS CAD 2.05, up 16% year-over-year, driven by revenue growth and expense control.
- Return on equity 13.0%, up 120 basis points year-over-year, management says ROE is tracking ahead of Investor Day expectations and they have increased confidence in hitting a 14%+ medium-term target.
- CET1 ratio 13.3% after repurchasing 4.9 million shares in Q1 under the NCIB; total buybacks to date were about 15.7 million shares, and management expects to renew the NCIB in May.
- +12 more takeaways
Brightstar Lottery Q4 2025 and FY2025 Earnings Call - Italy Lotto License Recasts Growth, €1.43B Final Installment Hits in Q2 2026
Brightstar completed a strategic transformation in 2025, exiting non-lottery gaming and emerging as a pure-play global lottery operator with stronger leverage metrics, a bigger shareholder-return prog...
- Brightstar completed a portfolio reshape in 2025, divesting the IGT gaming business and positioning itself as a focused, pure-play lottery operator. That strategic tidy-up underpins the company narrative on valuation and capital allocation going forward.
- Brightstar secured the Italy Lotto license for nine years, creating a platform to scale iLottery, iCasino, and sports betting across a retail footprint of over 50,000 points of sale. Management sees Italy as a core multi-year growth engine.
- The Italy license carries large upfront fees. Two installments were paid in 2025 and the final installment is EUR 1.43 billion (Brightstar’s share EUR 880 million, roughly $1 billion), expected to be paid in Q2 2026. That payment will materially affect reported cash from operations and leverage in the short term.
- +12 more takeaways
AdaptHealth Corp Q4 2025 Earnings Call - Largest industry capitated contract goes live early, setting up 2026 revenue and margin ramp
AdaptHealth closed a year of heavy remediation and operational consolidation by standardizing workflows, pruning non-core assets, and bringing the largest capitated HME contract in the industry live a...
- Company implemented a new operating model in 2025, standardizing workflows and centralizing order intake, which management says is driving faster setups and higher conversion rates.
- Full year 2025 revenue was $3.245 billion, Q4 revenue was $846.3 million, and organic revenue growth was 1.7% for both periods, excluding dispositions and acquisitions.
- AdaptHealth set patient census records in Sleep Health, Respiratory Health, and Wellness at Home, and achieved a retention record in Diabetes Health.
- +17 more takeaways
Keurig Dr Pepper Q4 2025 Earnings Call - JDE Peet’s Deal Recasts KDP into Two Pure-Play Companies with Near-Term EPS Accretion
Keurig Dr Pepper closed 2025 with solid top-line momentum and put a stake in the ground for a strategic pivot. Full-year constant currency net sales rose 8.6%, operating income 4.9%, and EPS 7.3%. Man...
- Corporate pivot front and center: KDP launched tender offer to acquire JDE Peet’s, expects early April close, and plans to separate into Beverage Co. and Global Coffee Co. by end of 2026.
- 2025 results: constant currency net sales +8.6%, operating income +4.9%, EPS +7.3% for the full year; Q4 net sales +9.9% and Q4 EPS $0.60, up ~1.7% year over year.
- 2026 guidance inclusive of JDE Peet’s: combined net sales $25.9B–$26.4B, low double-digit constant currency EPS growth; management expects ~6–7 percentage points of EPS contribution from JDE Peet’s over three quarters.
- +12 more takeaways
Henry Schein Fourth Quarter 2025 Earnings Call - Strong Sales Momentum, Back-Loaded Cost Savings and AI-Fueled Growth Guiding 2026
Henry Schein closed Q4 2025 with the strongest sales growth in 15 quarters, driven by record global equipment sales, double-digit gains in select implant brands, and continued traction in cloud practi...
- Q4 global sales were $3.4 billion, up 7.7% year over year, with constant currency growth of 5.8% and a 1.9% FX tailwind.
- Q4 non-GAAP operating margin was 7.42%, relatively flat year over year despite slight gross margin pressure from product mix shifts.
- Q4 GAAP net income was $101 million, or $0.85 per diluted share; Q4 non-GAAP net income was $160 million, or $1.34 per diluted share.
- +15 more takeaways
Orthofix International plc Q4 2025 Earnings Call - Channel Reset Delays Targets One Year, Sets Stage for VIRATA-Fueled Spine Rebound
Orthofix closed Q4 2025 with steady top-line progress and clear operational momentum, but with one important caveat. Management completed a deliberate spine distributor channel reset that pressured ne...
- Q4 2025 pro forma net sales were $218.6 million, up 3% year-over-year, excluding the discontinued M6 disc lines.
- Global spine fixation finished the year with 10% growth; US spine fixation grew 6% for the year and 5% in Q4.
- Management executed a targeted distributor transition in 2025 that caused temporary pressure but is now largely complete; top 30 US spine distributors grew 25% year-over-year and now drive more than 75% of US net sales.
- +15 more takeaways